Middle Management: Evaluating New Insights to Obesity and Weight Control Options
David Harlan, MD, Named Director, JDRF Center of Excellence, New England
The pharmacology data focus on the human body’s homeostatic response to potent HSD-1 inhibition by SPI-62. Results highlight that urinary free cortisol is distinct from intracellular cortisol that causes symptoms in patients with Cushing’s syndrome or autonomous cortisol secretion. Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology...
Goal-directed glycemic management in the hospital improves patient outcomes and reduces likelihood of readmission. ATLANTA—Hospitalized patients with diabetes or hyperglycemia who receive goal-directed glycemic management that includes new technologies for glucose monitoring and pre-discharge diabetes self-management education may have better outcomes and less likelihood of readmission, according to a Clinical Practice Guideline issued today by the Endocrine...